Cargando…
Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
BACKGROUND AND AIMS: Individuals with non‐alcoholic fatty liver disease (NAFLD) may be at greater risk of cancer. This study aimed to investigate the risk of hepatic and extrahepatic cancer compared to the general population in a population‐based cohort of patients with NAFLD. METHODS: We used the S...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306866/ https://www.ncbi.nlm.nih.gov/pubmed/35152526 http://dx.doi.org/10.1111/liv.15195 |
_version_ | 1784752636980887552 |
---|---|
author | Björkström, Karl Widman, Linnea Hagström, Hannes |
author_facet | Björkström, Karl Widman, Linnea Hagström, Hannes |
author_sort | Björkström, Karl |
collection | PubMed |
description | BACKGROUND AND AIMS: Individuals with non‐alcoholic fatty liver disease (NAFLD) may be at greater risk of cancer. This study aimed to investigate the risk of hepatic and extrahepatic cancer compared to the general population in a population‐based cohort of patients with NAFLD. METHODS: We used the Swedish National Patient Registry from 1987 to 2016 to identify patients with a NAFLD diagnosis and no prior cancer. All patients with NAFLD were compared to up to 10 controls matched for age, sex and living location. The primary outcome was the first occurrence of any cancer as ascertained from national registries. As secondary outcomes, we analysed the risk of pre‐specified cancer subtypes. Cox regression models, adjusted for baseline diabetes, hypertension, hyperlipidaemia and chronic obstructive pulmonary disease were applied. RESULTS: We identified 8415 patients with NAFLD. Over a median follow‐up of 6.0 years (IQR 2.5–11.2 years), an increased risk for any cancer was found in patients with NAFLD compared to controls (9.7 vs. 8.6 cases per 1000 person‐years): hazard ratio (HR) = 1.22 (95% confidence interval, CI = 1.12–1.33). The risk for hepatocellular carcinoma (HCC) was particularly high (adjusted HR, aHR = 12.18, 95% CI = 7.15–20.79). The risk for some other cancer subtypes increased (colorectal [aHR 1.38], kidney [aHR 2.12], bladder [aHR 2.51] and uterine [aHR 1.78]), but was low in absolute terms. CONCLUSION: In this population‐based cohort, NAFLD was associated with an increased risk of developing cancer (especially HCC). The absolute risk for other forms of cancer was generally comparable to the control population. |
format | Online Article Text |
id | pubmed-9306866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93068662022-07-28 Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study Björkström, Karl Widman, Linnea Hagström, Hannes Liver Int Metabolic & Toxic Liver Diseases BACKGROUND AND AIMS: Individuals with non‐alcoholic fatty liver disease (NAFLD) may be at greater risk of cancer. This study aimed to investigate the risk of hepatic and extrahepatic cancer compared to the general population in a population‐based cohort of patients with NAFLD. METHODS: We used the Swedish National Patient Registry from 1987 to 2016 to identify patients with a NAFLD diagnosis and no prior cancer. All patients with NAFLD were compared to up to 10 controls matched for age, sex and living location. The primary outcome was the first occurrence of any cancer as ascertained from national registries. As secondary outcomes, we analysed the risk of pre‐specified cancer subtypes. Cox regression models, adjusted for baseline diabetes, hypertension, hyperlipidaemia and chronic obstructive pulmonary disease were applied. RESULTS: We identified 8415 patients with NAFLD. Over a median follow‐up of 6.0 years (IQR 2.5–11.2 years), an increased risk for any cancer was found in patients with NAFLD compared to controls (9.7 vs. 8.6 cases per 1000 person‐years): hazard ratio (HR) = 1.22 (95% confidence interval, CI = 1.12–1.33). The risk for hepatocellular carcinoma (HCC) was particularly high (adjusted HR, aHR = 12.18, 95% CI = 7.15–20.79). The risk for some other cancer subtypes increased (colorectal [aHR 1.38], kidney [aHR 2.12], bladder [aHR 2.51] and uterine [aHR 1.78]), but was low in absolute terms. CONCLUSION: In this population‐based cohort, NAFLD was associated with an increased risk of developing cancer (especially HCC). The absolute risk for other forms of cancer was generally comparable to the control population. John Wiley and Sons Inc. 2022-02-24 2022-04 /pmc/articles/PMC9306866/ /pubmed/35152526 http://dx.doi.org/10.1111/liv.15195 Text en © 2022 The Authors. Liver International published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Metabolic & Toxic Liver Diseases Björkström, Karl Widman, Linnea Hagström, Hannes Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study |
title | Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study |
title_full | Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study |
title_fullStr | Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study |
title_full_unstemmed | Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study |
title_short | Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study |
title_sort | risk of hepatic and extrahepatic cancer in nafld: a population‐based cohort study |
topic | Metabolic & Toxic Liver Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306866/ https://www.ncbi.nlm.nih.gov/pubmed/35152526 http://dx.doi.org/10.1111/liv.15195 |
work_keys_str_mv | AT bjorkstromkarl riskofhepaticandextrahepaticcancerinnafldapopulationbasedcohortstudy AT widmanlinnea riskofhepaticandextrahepaticcancerinnafldapopulationbasedcohortstudy AT hagstromhannes riskofhepaticandextrahepaticcancerinnafldapopulationbasedcohortstudy |